Mounjaro at a Glance Mounjaro is a cutting-edge medication that belongs to a class of drugs known as GLP-1 agonists, similar to Ozempic
In fact, during phase 2 testing of the drug, liver fat dropped 43 percent with a lower dose and up to 82 percent with the higher dose in just 24 weeks
Common symptoms include: Muscle weakness Numbness Fatigue An irregular heartbeat On an ECG (electrocardiogram), doctors may observe specific changes, such as tall, peaked T-waves, a widened QRS complex, and flat P-waves
It belongs to a group of medications called GLP-1 receptor agonists, which mimic a natural hormone that regulates appetite and blood sugar
In the SURMOUNT-1 trial, participants without diabetes receiving tirzepatide experienced average weight losses of approximately 15%, 19.5%, and 20.9% of their baseline body weight over 72 weeks, depending on the dose administered
In the meantime, know the mechanism, understand the evidence, be honest with your patients about what we know and what we dont, and source it right
